Rawpixel/iStock via Getty Images
Lexaria Stock (NASDAQ:LEXX) rose 20% in morning trading Monday after the drug delivery company announced positive interim results from a small human pilot study that evaluated its DehydraTECH technology in the oral delivery of the GLP-1 drug Rybelsus, as well known as semaglutide.
Lexaria said Rybelsus, powered by DeyhdraTECH, was able to achieve higher sustained levels of semaglutide in the blood, along with faster peak drug delivery and reduced side effects compared to Rybelsus alone.
The biotechnology company said final results of the study should be available in December or January.
Lexaria also plans to begin an animal study of DehydraTECH GLP-1 in the first quarter of 2024. That study could be followed by a human clinical trial of DehydraTECH GLP-1 alone and in combination with DehydraTECH-CBD by the end of the second quarter or during the third quarter of 2024. He added that the studies are contingent on the company obtaining additional capital.
Rybelsus is an oral formulation of semaglutide from Novo Nordisk (NVO), which is used to treat diabetes. The medication is also marketed as an injectable product under the brand names Wegovy and Ozempic. Earlier this year, the FDA approved Wegovy for weight loss.
